Drug intelligence / Profile preview

brompheniramine + phenylephrine + phenylpropanolamine

Development stage
Unknown
Lead developer
National Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

D'TAPP Elixir is an over-the-counter (OTC) fixed-dose combination oral solution developed by National Pharmaceutical. It contains three active ingredients: brompheniramine (an antihistamine), phenylephrine (a decongestant), and phenylpropanolamine (a decongestant and sympathomimetic agent). Brompheniramine acts as an antagonist at the histamine H1 receptor to alleviate allergic symptoms such as sneezing, runny nose, and itchy eyes. Phenylephrine and phenylpropanolamine act as agonists at alpha-adrenergic receptors, causing vasoconstriction in the nasal mucosa to relieve nasal and sinus congestion. Phenylpropanolamine also stimulates the release of norepinephrine and inhibits its reuptake. D'TAPP Elixir is approved in Hong Kong (H.K. Registration Number HK-05475) for the symptomatic relief of the common cold, allergic rhinitis, and nasal congestion.

Brand names
D'TAPP Elixir
02

Targets

HRH1 (Histamine H1 Receptor)NET (Norepinephrine Transporter)ADRA1B (α1B)ADRA1D (α1D)ADRA2A (α2A)ADRB1 (β1)ADRB2 (β2)ADRA1A (α1A)

Beyond the preview

Go deeper on brompheniramine + phenylephrine + phenylpropanolamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on brompheniramine + phenylephrine + phenylpropanolamine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call